glp-1 obesity drug news october 2025 CVS deal puts Lilly on equal footing with Novo The Obesity-Drug Revolution Is Stalling
Description
We have answers
Koehler JA, Baggio LL, Yusta B, Longuet C, Rowland KJ, Cao X, et al
Common Misconceptions About GLP-1 Medications It is just an appetite suppressant. Not really
Assessment report Article 53 procedure for GLP-1-based therapies
However, it might also have more gastrointestinal side effects and a slightly higher risk of pancreatitis
In this issue of Ground Truths, Ill try and review this rapidly advancing field and where were headed
